علاج متلازمة الكارسينويد عندما لا يُحقق العلاج الإشعاعي بالمستقبلات الببتيدية PRRT مع 177Lutetium-DOTATATE السيطرة الكافية على الأعراض

References

DOI: 10.1111/jne.13146

• A small series demonstrated that everolimus combined with octreotide LAR led to symptom relief in RCS.
• Despite its low evidence as an anti-secretory agent, everolimus has proven antitumour activity in NET and can be considered in RCS patients.
• The anti-secretory effects of interferon alpha (IFN-α) may be useful in RCS patients.
• The recommended dose of IFN-α is 3–9 MU s.c. every other day. A slow-release formulation of 50–100 μg PEGylated IFN-α is given s.c. once a week.